Comparison of IORT (Radical and Boost Dose) and EBRT in Terms of Disease-Free Survival and Overall Survival according to Demographic, Pathologic, and Biological Factors in Patients with Breast Cancer

Table 1

IRIORT consensus protocol for radical dose.

Patients’ factors	Suitable	Possible	Contraindicated
Age	50≤	45–50	<45
Tumor size	≤3	3–3.5	≥3.5
Margins	Negative	Negative	Positive
Grade	1 and 2	Any	—
LVI	Negative	Any	Positive
ER status	Positive	Any	—
Multicentricity	No	No	Yes
Multifocality	No	Yes	—
IDC	Yes	Yes	—
ILC	Yes	Yes	—
Pure DCIS	≤3 cm	3-4 cm	>4 cm
EIC	<25%	≥25%	Diffuse
Her2	Any	—	—
Ki67	<30%	≥30%	—
Nodal status	Negative	Negative (i−, i+)	Positive
Axillary surgery	SLNB	SLNB, ALND	—
Neoadjuvant treatment	Not allowed	Not allowed	If used

LVI, lymphovascular invasion; EIC, extensive in situ component; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ.